Factors Associated with Greater Adherence to and Satisfaction with Transdermal Rivastigmine in Patients with Alzheimer's Disease and Their Caregivers

Dementia and Geriatric Cognitive Disorders

Volumn 40, Issue 1-2, 2015, Pages 107-119

  Riepe, Matthias ^a   Weinman, John ^c   Osae Larbi, Judith ^d   Mulick Cassidy, Amy ^d   Knox, Sean ^e   Chaves, Ricardo ^e   Müller, Beate ^b  

^a UNIVERSITY OF ULM   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d Atlantis Healthcare ^*  (United Kingdom)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Acetylcholinesterase inhibitor; Adherence to medication; Alzheimer's disease; Caregivers; Rivastigmine; Satisfaction; Transdermal patch

Indexed keywords

RIVASTIGMINE; CHOLINESTERASE INHIBITOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; CONTROLLED STUDY; DRUG INFORMATION; FEMALE; FOLLOW UP; HOME CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; SOCIAL PSYCHOLOGY; VERY ELDERLY; CLINICAL TRIAL; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; PSYCHOLOGY; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CAREGIVERS; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT SATISFACTION; RIVASTIGMINE; SURVEYS AND QUESTIONNAIRES; TRANSDERMAL PATCH;

EID: 84930888855     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000381894     Document Type: Article

References (26)

1. Bassil N, Thaipisuttikul P, Grossberg GT: Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease. Expert Opin Pharmacother 2010; 11: 1765-1771.
2. Massoud F, Gauthier S: Update on the pharmacological treatment of Alzheimer's disease. Curr Neurophar-macol 2010; 8: 69.
3. Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 1:CD005593.
4. Small G, Dubois B: A review of compliance to treatment in Alzheimer's disease: potential benefits of a trans-dermal patch. Curr Med Res Opin 2007; 23: 2705-2713.
5. Lyle S, Grizzell M, Willmott S, et al: Treatment of a whole population sample of Alzheimer's disease with done-pezil over a 4-year period: lessons learned. Dement Geriatr Cogn Disord 2008; 25: 226-231.
6. Brady R, Weinman J: Adherence to cholinesterase inhibitors in Alzheimer's disease: a review. Dement Geriatr Cogn Disord 2013; 35: 351-363.
7. Bernabei R, Rossini PM, Di Cioccio L, et al: Compliance and caregiver satisfaction in Alzheimer's disease: results from the AXEPT study. Dement Geriatr Cogn Disord Extra 2012; 2: 418-432.
8. Boada M, Arranz FJ: Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine. Dement Geriatr Cogn Disord 2013; 35: 23-33.
9. Darreh-Shori T, Jelic V: Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. Expert Opin Drug Saf 2010; 9: 167-176.
10. Chan AL, Chien YW, Lin SJ: Transdermal delivery of treatment for Alzheimer's disease. Drug Aging 2008; 25: 761-775.
11. Guay D: Rivastigmine transdermal patch: role in the management of Alzheimer's disease. Consult Pharm 2008; 23: 598-609.
12. Nunes V, Neilson J, O'Flynn N, et al: Medicines Adherence: Involving Patients in Decisions about Prescribed Medicines and Supporting Adherence. London, National Collaborating Centre for Primary Care and Royal College of General Practitioners, 2009, p 364.
13. Broadbent E, Petrie KJ, Main J, et al: The Brief Illness Perception Questionnaire. J Psychosom Res 2006; 60: 631-637.
14. Horne R, Weinman J, Hankins M: The Beliefs about Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999; 14: 1-24.
15. Petrie KJ, Perry K, Broadbent E, et al: A text message programme designed to modify patients' illness and treatment beliefs improves self-reported adherence to asthma preventer medication. Br J Health Psychol 2012; 17: 74-84.
16. Jackson CA, Clatworthy J, Robinson A, Horne R: Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol 2010; 105: 525-539.
17. Horne R, Weinman J: Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health 2002; 17: 17-32.
18. Abetz L, Rofail D, Mertzanis P, et al: Alzheimer's disease treatment: assessing caregiver preferences for mode of treatment delivery. Adv Ther 2009; 26: 627-644.
19. Kroenke K, Spitzer RL, Williams JB, et al: Anxiety disorders in primary care: prevalence, impairment, comor-bidity, and detection. Ann Intern Med 2007; 146: 317-325.
20. Kroenke K, Spitzer RL, Williams JB: The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care 2003; 41: 1284-1292.
21. Horne R, Hankins M, Jenkins R: The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. Qual Health Care 2001; 10: 135-140.
22. Faul F, Erdfelder E, Buchner A, Lang AG: Statistical power analyses using G ∗ Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009; 41: 1149-1160.
23. Cohen J: Statistical Power Analysis for the Behavioral Sciences, ed 2. New Jersey, Lawrence Erlbaum, 1988.
24. Morisky D, Green L, Levine D: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 4: 67-74.
25. Ruiz M, Pardo A, Rejas J, et al: Development and validation of the 'Treatment Satisfaction with Medicines Questionnaire' (SATMED-Q). Value Health 2008; 11: 913-926.
26. Garfield S, Clifford S, Eliasson L, et al: Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review. BMC Med Res Methodol 2011; 11: 149.